Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
- Today's Annual General Meeting was the first one following the change in legal form completed in
November 2023 - Shareholders voted in favor of the proposed dividend of
1.19 euros , representing an increase of around 6 percent compared to the previous year - New compensation system for Management Board approved
- Ambitious growth targets for 2024 confirmed
BAD HOMBURG,
At today's Annual General Meeting,
"Turning to 2024, this year is being spent in singular focus on disciplined execution and value creation. While 2023 was a year of level-setting, 2024 is one of momentum-building," said Giza. The CEO thanked employees for their dedication and commitment to ensuring high-quality care for patients worldwide.
A significant majority of 96.97 percent of shareholders approved the dividend proposal for fiscal year 2023 of
The shareholders also approved, with a majority of 87.58 percent, the new Management Board's compensation system.
With a majority of 99.49 percent, the shareholders also approved the update to the Supervisory Board's remuneration.
The Management Board and the Supervisory Board were discharged for the year 2023 with majorities of 98.71 percent and 98.42 percent, respectively.
At the Annual General Meeting, 88.39 percent of the share capital was represented.
About
For further information, please visit www.freseniusmedicalcare.com/de.
Legal Disclaimer:
This communication contains forward-looking statements, which are subject to various risks and uncertainties. Future results may differ significantly from the currently expected results due to various factors such as changes in the business, economic, and competitive situation, changes in laws, regulatory approvals, the impact of the Covid-19 pandemic, results of clinical studies, exchange rate fluctuations, uncertainties regarding litigation or investigative proceedings, and the availability of financial resources. These and other risks and uncertainties are described in detail in the reports of
Media Contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for Analysts and Investors
Dr.
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com/de
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-annual-general-meeting-company-makes-significant-progress-in-its-transformation-efforts-and-confirms-its-ambitious-2024-growth-targets-302147875.html
SOURCE